If this vaccine is used, one-third of primate will be saved

Although the initial results of this vaccine are very promising, changes related to new medical research regulations on primates can limit more intensive experiments.

After the Ebola outbreak in West Africa in 2014, scientists worked continuously to develop a treatment for this deadly disease to slow or completely prevent the next outbreak.

While human therapies are being tested in animals, another group of scientists continues to create an Ebola vaccine to protect primates in nature.

Although the initial results are promising, changes related to new medical research regulations on primates may limit more intensive experiments.

Ebola not only strikes every human being but also a very real threat to primates.

Last year, a new Ebola vaccine trial conducted in Guinea and Sierra Leone showed good results. But in fact, Ebola not only strikes each person but also a very real threat to primates.

In November and December 1994, scientists discovered that all wild chimpanzee communities living in Taïo National Park in Côte d'Ivoire have disappeared. The last reason is that all chimpanzees have been infected with the new Ebola virus.

In 2011, another study warned that Ebola was the cause of killing "about one third of the world's gorilla population and the same rate as chimpanzees" . With the primate populations lacking habitat and poaching, the spread of the disease is indeed an alarming issue.

1/3 of the primate population are killed by the Ebola virus

In this situation, scientists have focused on creating a vaccine exclusively for wild primates. In a study published last week in the Scientific Results workshop, the researchers found that a novel oral vaccine test "stimulates a strong immune response" with 10 sperms. Refined use in research.

The research team especially wanted to know the actual effectiveness of oral vaccines compared to the vaccination methods used to protect wild populations from epidemics such as rabies. With this new form, instead of tracking wild animals for vaccination - which is extremely difficult to apply to primates in Africa - it is easy to put vaccines into bait and wait for animals to eat them. Much easier.

The vaccine, called filorab1, was made from an inactivated wild virus with an Ebola insertion gene that was tested and yielded more than expected.

After 28 days since the chimpanzees were vaccinated - 6 doses and 4 injections, scientists will take blood to review the results. The scientists found that the vaccine had the same level of protection as previous tests of filorab1 with a "strong immune response" in the first 28 days of the trial. It is really a signal for them to reach full immunity to many different hosts.

Although very promising, the study is still subject to limited supervision because of changes.

However, things didn't go well. In June 2015, the US Fish and Wildlife Service listed chimpanzees and Endangered Species Act, somewhat obstructing current research.

As a result, scientists can only take blood after 28 days for research and cannot continue the "Ebola challenge" , the test to test the vaccine's ability to enhance immunity to infected animals. sick.

The authors of the study noted that research that favored primates was exempted from new regulations, but due to changes related to "all biomedical facilities containing chimpanzees need to be taking them to suitable protected areas " will limit the type of experiments involved.

New Scientists pointed out that, until conservation experts and health officials agreed on a new plan, the vaccine would never be deployed for wildlife.